The chromatin remodeling complex PRC2 safeguards cell fate in alveolar epithelial type 2 cells

This study demonstrates that the chromatin remodeling complex PRC2 is a conserved critical regulator that safeguards alveolar epithelial type 2 (AT2) cell fate by preventing their aberrant transition into alveolar-basal intermediate and basal-like states, thereby maintaining lung homeostasis and preventing emphysematous remodeling.

The Gist

Imagine your lungs are a bustling, high-tech city. The most important workers in the "gas exchange district" (the alveoli, where oxygen enters your blood) are the AT2 cells. Think of these cells as the master architects and maintenance crews. They do two vital jobs:

1. They produce a special "soap" (surfactant) that keeps the tiny air sacs from collapsing.
2. When the city gets damaged (by a virus, smoke, or injury), they are the only ones who can clone themselves to replace lost workers or transform into new types of workers (AT1 cells) to repair the walls.

For the city to function, these architects need to stay focused on their job. They need to remember, "I am an AT2 cell, and I must stay an AT2 cell."

The "Identity Guard" (PRC2)

This is where the star of the paper comes in: PRC2. You can think of PRC2 as a strict identity guard or a digital lock on the architects' computers.

• What it does: It locks away the blueprints for "other jobs" (like becoming a basal cell, which is a different type of worker usually found in the airways, not the deep lungs).
• Why it's needed: When the architects are busy dividing to make new copies of themselves (self-renewal), there's a risk they might get confused and accidentally start building the wrong kind of structures. PRC2 ensures that even while they are busy multiplying, they don't lose their "AT2" identity.

What Happens When the Guard is Fired?

The researchers decided to see what happens if they remove this "identity guard" (PRC2) from the AT2 cells. They did this in two ways: in human cells grown in a lab dish and in the lungs of mice.

The Result: A City in Chaos
Without the guard, the AT2 cells started to forget who they were.

1. The Confusion Phase: First, the cells became "confused intermediates." In the paper, these are called ABI cells (Alveolar-Basal Intermediate). Imagine an architect who stops drawing blueprints for air sacs and starts looking at blueprints for a subway station, but hasn't finished the switch yet. They are stuck in a weird, stressed state.
2. The Wrong Turn: Eventually, these confused cells completely gave up being AT2 cells. They transformed into basal-like cells. These are cells that belong in the upper airways (like the trachea), not the deep lungs.
3. The Disaster: Because the deep lungs are now filled with the wrong type of cells, the air sacs can't function properly. The walls of the air sacs break down, leading to emphysema (a condition where you lose the surface area needed to breathe). In the mice, this looked like their lungs were slowly turning into a sieve with huge holes in them.

The Human Connection

The researchers also looked at human lung disease, specifically fibrosis (scarring of the lungs). They found that in sick human lungs, the "identity guard" (PRC2) was broken or missing. The human cells were going through the exact same confused journey: AT2 cell $\rightarrow$ Confused Intermediate $\rightarrow$ Wrong-type Basal cell.

This suggests that many chronic lung diseases aren't just about "scarring"; they are about cellular identity theft. The cells are losing their memory of what they are supposed to be because the epigenetic locks (PRC2) have been broken.

The Big Takeaway

Think of your lung cells like actors in a play.

• AT2 cells are the lead actors playing the "Architect" role.
• PRC2 is the script supervisor making sure they stay in character.
• Injury or disease is like a chaotic backstage environment.

If the script supervisor (PRC2) is fired, the lead actors forget their lines, start improvising, and eventually try to play a completely different character (the "Basal" role) that doesn't fit the scene. The play falls apart, and the lung stops working.

Why this matters:
This discovery is huge because it identifies a specific "lock" (PRC2) that keeps our lungs healthy. If scientists can find a way to fix this lock or strengthen it in people with lung disease, they might be able to stop the cells from turning into the wrong type, potentially reversing damage or preventing emphysema and fibrosis in the future. It's like realizing that to fix a broken city, you don't just patch the holes; you need to retrain the workers to remember their jobs.

Technical Summary

1. Problem Statement

The adult lung relies on Alveolar Epithelial Type 2 (AT2) cells as facultative progenitors to maintain the gas-exchange surface and regenerate tissue after injury. While the signaling pathways (WNT, FGF) driving AT2 proliferation and differentiation are known, the epigenetic mechanisms that maintain AT2 cell identity during self-renewal and prevent aberrant differentiation remain poorly understood.

• The Gap: It is unclear how AT2 cells epigenetically "remember" their fate during cell division and what happens when these regulatory mechanisms fail.
• The Hypothesis: The Polycomb Repressive Complex 2 (PRC2), a chromatin modifier that deposits repressive H3K27me3 marks, is essential for maintaining AT2 cell fate and preventing the transition to pathological intermediate or basal-like states.

2. Methodology

The study employed a multi-modal approach combining in vitro human models, in vivo murine genetics, and single-cell genomics:

• Human In Vitro Models:

  • Used human induced pluripotent stem cell-derived AT2 (iAT2) cells.
  • Proliferation Kinetics: Performed EdU labeling and time-series scRNA-seq to map the cyclical relationship between proliferation and maturation.
  • Functional Manipulation: Used small molecule inhibitors (GSK126, DZNep) and shRNA to knock down EZH2 (the catalytic subunit of PRC2), and lentiviral overexpression to increase EZH2.
  • Differentiation Assays: Tested the capacity of iAT2s to differentiate into AT1 cells under PRC2 inhibition.

• Murine In Vivo Models:

  • Conditional Knockout (CKO): Generated Sftpc^CreERT2 x Eed^fl/fl and Ezh2^fl/fl mice to induce AT2-specific deletion of PRC2 components in adult mice (6–8 weeks old) via tamoxifen.
  • Lineage Tracing: Used R26R^YFP or R26R^tdTomato reporters to track the fate of PRC2-deficient AT2 cells over 2, 4, and 9 months.
  • Phenotyping: Conducted histology (H&E), immunofluorescence (IF) for markers (SPC, HOPX, KRTs, p63), and morphometric analysis (Mean Linear Intercept).

• Single-Cell Genomics:

  • scRNA-seq: Performed on human iAT2s and sorted YFP+ epithelial cells from murine lungs at multiple time points.
  • Analysis: Used Seurat for integration, Monocle3 for pseudotime trajectory analysis, and scTOP (single cell type order parameters) to project murine mutant cells onto reference atlases (uninjured mouse, injured mouse, human IPF).

• Comparative Analysis:

  • Re-analyzed published datasets of human IPF and in vitro human AT2-to-basal transdifferentiation to compare with murine PRC2-loss data.

3. Key Contributions

1. Identification of PRC2 as a Proliferation-Specific Regulator: Demonstrated that PRC2 components (EZH2, SUZ12) are specifically upregulated in proliferating AT2 cells across human and mouse species, suggesting a role in maintaining identity during cell division.
2. Definition of the "Alveolar-Basal Intermediate" (ABI) State: Characterized a specific, definable transitional state (ABI) that AT2 cells pass through when PRC2 is lost, serving as a bridge between alveolar and basal identities.
3. Conservation of Mechanism: Provided evidence that the mechanism of AT2-to-basal transdifferentiation via an ABI state is conserved between mice and humans, and is directly linked to the loss of PRC2 function.
4. In Vivo Pathogenesis Model: Established that genetic loss of PRC2 in adult mice is sufficient to cause spontaneous emphysema and progressive loss of AT2 fate, mimicking aspects of chronic lung disease.

4. Key Results

• PRC2 Activation in Cycling AT2s:

  • In human iAT2s, proliferation peaks 2–5 days post-passage, followed by a maturation peak (SFTPC expression) at day 7.
  • Cross-species scRNA-seq analysis revealed that EZH2 and SUZ12 are highly enriched in proliferating AT2 populations compared to quiescent ones.

• Loss of AT2 Identity In Vitro:

  • Inhibiting EZH2 (via GSK126 or shRNA) in human iAT2s and murine organoids led to:
    • Downregulation of AT2 markers (SFTPC, SFTPA1/2, NKX2-1).
    • Upregulation of stress/intermediate markers (SOX9, KRT8, KRT7).
    • Impaired differentiation into AT1 cells.
  • Conversely, EZH2 overexpression enhanced the AT2 program.

• Progressive Fate Drift In Vivo (The "Time-Dependent" Model):

  • In Eed^CKO mice, AT2 cells initially appeared normal at 2 months.
  • 4 Months: Emergence of KO_AT2 cells (SFTPC⁺/KRT8^hi) and ABI cells (SFTPC^low/KRT7^hi/KRT8^hi/CLDN4⁺).
  • 9 Months: Complete loss of AT2 identity in the lineage. Cells transitioned to Basal-like states (KRT5^hi/KRT17^hi/TP63⁺).
  • Phenotype: This transition resulted in emphysematous remodeling (simplified alveoli, increased mean linear intercept) and interstitial thickening, despite no increase in cell death.

• Molecular Trajectory:

  • Pseudotime analysis confirmed a linear trajectory: AT2 $\rightarrow$ KO_AT2 $\rightarrow$ ABI $\rightarrow$ Basal-like.
  • This trajectory involved the derepression of canonical PRC2 targets, including cell cycle inhibitors Cdkn1a (p21) and Cdkn2a (p16), which are associated with senescence and disease.

• Human Relevance:

  • Re-analysis of human IPF tissue and in vitro differentiation models showed that human ABI cells (KRT7⁺/KRT17⁺) also exhibit derepression of PRC2 targets.
  • Inhibiting EZH2 in human iAT2s recapitulated the upregulation of KRT5 and KRT17, confirming PRC2 is a conserved guardrail against basal transdifferentiation.

5. Significance and Implications

• Mechanistic Insight: The study defines PRC2 as a critical "guardrail" that prevents AT2 progenitors from drifting into pathological basal-like states during self-renewal. Without PRC2, the AT2 epigenetic state is unstable, leading to a default drift toward a basal identity.
• Disease Pathogenesis: The findings suggest that chronic lung diseases (like IPF and emphysema) may be driven by epigenetic stress that compromises PRC2 function, leading to the accumulation of aberrant intermediate cells (ABIs) that fail to regenerate functional alveoli.
• Therapeutic Potential:
  • PRC2 components (EZH2) represent potential therapeutic targets. Enhancing PRC2 activity could stabilize AT2 fate and prevent fibrotic remodeling.
  • Conversely, understanding the "ABI" state provides a new target for clearing pathological cells in fibrotic lungs.
• Paradigm Shift: Challenges the view that basal cells are only proximal airway cells; it suggests that under epigenetic stress, distal alveolar cells can transdifferentiate into basal-like cells, a process normally suppressed by PRC2.

In summary, this paper establishes that the PRC2 complex is essential for the epigenetic maintenance of AT2 cell fate, and its failure drives a conserved, time-dependent transition from alveolar to basal-like states, contributing to the pathogenesis of chronic lung remodeling.